Key points
- 42% increase in full-year revenue to $15.8M
- Returned to full-year profitability with net profit after tax of $1.5M
- Positive operating cashflow in every quarter
- FY27 guidance: revenue of $17M to $22M
- Normalised EBITDA of $2.6M to $3.6M
Full summary
Resonance Health Limited (ASX: RHT) announced its full-year results for the year ended 30 June 2026, reporting a 42% increase in revenue to $15.8M and a return to full-year profitability with a net profit after tax of $1.5M. The company achieved positive operating cashflow in every quarter, with net cash from operating activities of $2.9M and free cashflow of $2.8M. The company also provided FY27 guidance of $17M to $22M revenue and $2.6M to $3.6M Normalised EBITDA, based on modest assumptions. The company's three business units, including clinical trial management services, clinical trial site services, and software-as-a-medical device image analysis services, all contributed to the strong financial performance. The company's CEO, Mr. Andrew Harrison, expressed confidence in the company's strategy to scale its integrated healthcare technology and clinical services platform.
Guidance
FY27 guidance: revenue of $17M to $22M and Normalised EBITDA of $2.6M to $3.6M
Outlook
The company is confident in its strategy to scale its integrated healthcare technology and clinical services platform, with contracted invoicing milestones into FY27, a record SaMD forward orders and bid-tender pipeline, and expanding and increasingly profitable TrialsWest clinical trial site operations.